Guangyao group introduces three new anti-tumor drugs under development

According to reports, the innovation team selected this time is the first innovation team of Guangdong Province obtained by Guangyao group There are seven core members The team has been engaged in the research and development of targeted anti-tumor drugs for a long time, including experts in translational medicine and clinical research, drug target and design, pharmaceutical research and industrialization, preparations and processes, pharmaceuticals and synthesis, regulatory registration and quality, etc Among them, three core members are special experts of China's "thousand talents plan" The team leader, Dr Zhai Yifan, is a doctor of pharmacology and toxicology from Michigan State University in the United States He has nearly 25 years of experience in innovative drug research and development and enterprise management He is the co inventor of solafeni, the first drug for renal cancer approved by FDA in the past 10 years According to Gu lie, a core member of the innovation team, the recently released cancer registration data in China shows that there are about 3.12 million new cancer cases in China every year, with an average of 8550 people recruited every day, 6 people diagnosed with cancer every minute, 5 people died of cancer, and the probability of cancer in people's life is 22% Among them, lung cancer, gastric cancer and liver cancer have become the highest incidence and mortality cancer The innovation team will focus on the three particularly high incidence tumors in China and carry out three new drug research and development: hqp8361 is used for targeted treatment of gastric cancer, non-small cell lung cancer and liver cancer, It is expected that the new drug certificate and production approval will be obtained in 2018, which will become the first high selective second generation of small molecule targeted anti-tumor drugs acting on c-met kinase in China Hqp7015 is the first in the world to be used in the treatment of osteosarcoma, primary liver cancer and gastric cancer At present, similar drugs are in the research and development stage, and there is no drug research and development in this field in China Hqp1351 is expected to be one of the first batch of the third generation BCR ABL kinase small molecule inhibitors in the treatment of chronic myeloid leukemia and gastric stromal tumor It is reported that the incidence rate of malignant tumors has been increasing in recent years, and the anti-cancer drugs have a good market performance It is understood that in 2012, new targeted anti-tumor drugs, such as Gleevec, made more than 30 billion US dollars and 20 billion yuan of market sales, with an annual growth rate of more than 20% Based on the strong market demand, the research and development of anti-tumor drugs has become a critical place for domestic and foreign pharmaceutical companies to invest heavily, and the competition is also extremely fierce The safety, effectiveness and novelty of products are directly related to the future market Gu said the three new drugs are new molecular targeted anti-tumor drugs Compared with similar drugs, the original 1.1 developed by the team Class a new drugs are all original drugs with new chemical structure, with higher activity or stronger safety and other technical advantages, especially with good biomarkers used to select patients for personalized treatment, which is expected to replace the existing clinical drugs as first-line drugs, with broad market prospects "Once these drugs are successfully listed, they will make up for the lack of a new drug in Guangdong Province in recent years, and at the same time, they will quickly form a large-scale sales When the project market is mature, it is expected to achieve sales of more than 10 billion yuan." Gu said Li Chuyuan, chairman of Guangyao group, the team leader, said that each of the three class 1.1 new drugs would cost 500 million to 1 billion yuan Li Chuyuan, chairman of Guangyao group, said that 2014 is the year of scientific research layout of Guangyao Guangyao will increase investment in scientific research and accelerate the transformation of new drug research and innovation achievements He also revealed that "we will also explore a variety of new modes of foreign scientific research cooperation, such as" project fund mode "," school local collaborative innovation mode "," project backbone member shareholding mode " Li also pointed out that Guangyao continued to speed up the research and development of double plasmid HBV DNA vaccine and industrialization research projects, as well as the research and development of other biological medicines such as gene diagnosis and individualized molecular diagnosis and treatment, and carried out "strong imitation" and "first imitation" of drugs with patent expiration In addition, Viagra, the first generic drug, is expected to go on the market within this year.